PATIENT PACKAGE INSERT IN ACCORDANCE WITH THE PHARMACISTS' REGULATIONS (PREPARATIONS) - 1986 The medicine is dispensed with a doctor's prescription only

OPDIVO

Concentrate for solution for intravenous infusion The active ingredient and its concentration:

nivolumab 10 mg/m

For the list of inactive ingredients and allergens, please see section 2 under 'Important information about some of this medicine's ingredients' and section 6 'Further information'.

Read this leaflet carefully in its entirety before using the medicine. This leaflet contains concise information about the medicine. If you have further questions, refer to the doctor or pharmacist.

If the treating doctor prescribes you OPDIVO in combined treatment with ipilimumab, carefully read the patient leaflet that comes with ipilimumab as well. If the treating doctor prescribes you OPDIVO in combined treatment with cabozantinib, carefully read the patient leaflet that comes with cabozantinib as well.

This medicine has been prescribed for the treatment of your ailment. Do not pass it on to others. It may harm them, even if it seems to you that their ailment is similar

This leaflet does not take the place of talking with your treating doctor about your medical condition or your treatment.

Patient pocket guide and patient safety information card In addition to the leaflet, patient pocket guide and patient safety information card are available for OPDIVO.

The pocket guide and the card contain important safety informatio which you have to know before and during the treatment with OPDIVO, and which you must follow. Review the patient pocket guide, the patient safety information card and the patient leaflet before you start using the medicine. Keep the card and the pocket guide for further review if required.

1. WHAT IS THIS MEDICINE INTENDED FOR?

OPDIVO is used to treat · A type of skin cancer called melanoma

- OPDIVO used alone or in combination with ipilimumab is indicated for treatment of adults and children 12 years of age and older with advanced (unresectable or metastatic) melanoma.
- OPDIVO is indicated as complementary (adjuvant) treatment for adults and children 12 years of age and older with Stage IIB, IIC, III or IV melanoma after complete resection

Non-small cell lung cancer

OPDIVO, in combination with platinum-doublet chemotherapy, is indicated as treatment before surgery (neoadjuvant) of adult patients with resectable

- (tumors \geq 4 cm or involve lymph nodes) non-small cell lung cancer. OPDIVO, in combination with ipilimumab and 2 treatment cycles of combined platinum-containing chemotherapy (platinum-doublet chemotherapy), is indicated as first-line treatment for adults with metastatic or recurrent non-small cell lung cancer with no changes in the EGFR or ALK genes in
- the tumor. OPDIVO is indicated for treatment of adults with metastatic non-small cell lung cancer whose disease has progressed during treatment or after treatment with platinum-based chemotherap
- Malignant pleural mesothelioma, cancer of mesothelial cells comprising the pleura (lining of the lungs) OPDIVO in combination with ipilimumab is indicated as first-line treatment for
- adults with unresectable malignant pleural mesothelioma.
- Advanced renal cell carcinoma OPDIVO in combination with ipilimumab is indicated as first-line treatment.
- for adults with advanced renal cell carcinoma at moderate or high risk. OPDIVO in combination with cabozantinib is indicated as first-line treatment for adults with advanced renal cell carcinoma
- OPDIVO used alone is indicated for the treatment of adults with advanced renal cell carcinoma who have received prior anti-angiogenic therapy.
- Classical Hodgkin lymphoma (a type of blood cancer) OPDIVO is indicated for treatment of adults with classical Hodgkin lymphoma
- that has come back or spread after a stem cell transplant that uses your own stem cells (autologous), and treatment with brentuximab vedotin medicine or
- 3 or more systemic treatment lines including a stem cell transplant that uses vour own stem cells (autologous).

Squamous cell head and neck cancer (squamous cell carcinoma) OPDIVO is indicated for treatment of adults with recurrent or metastatic squamous cell head and neck cancer whose disease has progressed during

or following platinum-based chemotherapy. Urothelial carcinoma (urinary tract or bladder cancer)

- OPDIVO is indicated as complementary (adjuvant) treatment for adults with urinary tract or bladder cancer at high risk of disease recurrence after radical
- tumor resection. OPDIVO is indicated for treatment of adults with locally advanced or
- metastatic urinary tract or bladder cancer after their disease has progressed during or following platinum-based chemotherapy.
- after their disease has progressed during 12 months following platinum-based chemotherapy given prior to tumor resection surgery (neoadjuvant) or as complementary (adjuvant) therapy post-surgery.

Metastatic colon or rectal cancer (colorectal cancer)

OPDIVO used alone or in combination with ipilimumab is indicated for treatment of adults and children aged 12 years and older with metastatic colorectal cancer expressing dMMR (mismatch repair deficient) or MSI-H (microsatellite instability-high), whose disease has progressed following treatment with fluoropyrimidine, oxaliplatin, and irinotecan Liver cancer (hepatocellular carcinoma)

OPDIVO used alone or in combination with ipilimumab, is indicated for the treatment of adults with liver cancer with mild liver impairment (Child-Pugh A) following treatment with sorafenib.

Esophageal cancer

- OPDIVO is indicated for the complementary (adjuvant) treatment after complete resection of esophageal cancer or gastroesophageal junction 4. SIDE EFFECTS cancer with residual pathological disease in adults treated with chemoradiotherapy (CRT) prior to resection.
- OPDIVO, in combination with fluoropyrimidine and platinum-based bination chemotherapy, is indicated for the first-line treatment of adult patients with unresectable, advanced, recurrent or metastatic esophageal squamous cell carcinoma with PD-L1 expression in \geq 1% of the tumor cells. OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable, advanced, recurrent or metastatic esophageal squamous cell carcinoma with PD-L1 expression in \geq 1% of the tumor cells.
- OPDIVO is indicated for treatment of adults with unresectable, advanced. recurrent or metastatic esophageal squamous cell carcinoma after prior treatment with fluoropyrimidine and platinum-based chemotherapy.

 Gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma

OPDIVO in combination with fluoropyrimidine and platinum containing chemotherapy is indicated for treatment of adults with unresectable, advanced or metastatic gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma

Therapeutic group: antineoplastic agent.

2. BEFORE USING THE MEDICINE:

Do not use this medicine if:

• you are sensitive (allergic) to the active ingredient (nivolumab) or to any of the other ingredients in this medicine (see section 6).

Special warnings regarding use of this medicine

Before treatment with OPDIVO, tell the doctor about all of your medical conditions, including if: • you have problems involving the immune system such as Crohn's disease,

- ulcerative colitis, or lupus
- you have had an organ transplant • you have received or are about to receive a stem cell transplant that uses donor stem cells (allogeneic)
- you have received radiation treatment to your chest area in the past and have received other medicines that are like OPDIVO • you have a condition that affects your nervous system, such as severe muscle
- weakness (myasthenia gravis) or Guillain-Barré syndrome
- you are pregnant or plan to become pregnant (see the section 'Pregnancy and breastfeeding') • you are breastfeeding or plan to breastfeed (see the section 'Pregnancy and breastfeeding')
- urinating more often than usual hair loss
 - feeling cold

Children and adolescents

There is no information regarding the efficacy and safety of OPDIVO: in children below the age of 12 with melanoma or metastatic colorectal cancer expressing dMMR or MSI-H. or

swollen stomach (abdomen) due to fluid accumulation (ascites)

foot drop or typical limping (peroneal nerve palsy)

muscles pain, muscles weakness not due to exercise (myopathy)

• chronic joints inflammation usually involving the spinal joints

Uncommon side effects, affect 1-10 patients in 1000 users:

bleeding from esophageal varices

drv mouth

• flu

chills

flu-like illness

• death due to side effects

· respiratory tract infection

(spondyloarthropathy)

muscles inflammation (myositis)

lacrimal and salivary glands

nerve inflammation (neuritis)

• paralysis of the fibular nerve in the leg characterized by pain in the calf,

• Sjogren's syndrome, a disease in which the immune system attacks mainly

decreased sensation or numbness, muscle weakness, and in severe cases

 in children for the treatment of other cancer types Tests and follow up:

The treating doctor will perform blood tests to monitor side effects

Drug interactions: If you are taking, or have recently taken, other medicines, including non-prescription medicines and nutritional supplements, tell the doctor o harmacist

Pregnancy and breastfeeding

OPDIVO may harm your unborn baby. Nomen who are able to become pregnant:

- e treating doctor should perform a pregnancy test before you start receiving OPDIVO. • You should use an effective method of birth control during treatment and for all of the signs and symptoms of immune system problems that may 5 months after receiving the last dose of OPDIVO. Consult your treating doctor about birth control methods that you can use during this time.
- Tell the treating doctor right away if you become pregnant during treatment with OPDIVO.

3reastfeeding Do not breastfeed during treatment with OPDIVO and for 5 months after taking • double vision, blurry vision, sensitivity to light, eye pain, changes in eyesight the last dose of OPDIVO. It is not known whether OPDIVO can pass into your oreast milk

Driving and operating machinery

for an adult.

Exercise caution when driving or using any tools or machines until you are certain **from becoming more serious**. that OPDIVO does not adversely affect you as a result of potential side effects see section 4)

Children should be warned against riding bicycles or playing near the road, etc. Important information about some of this medicine's ingredients **OPDIVO** contains sodium.

f you consume a low sodium (low salt) diet, inform your doctor prior to administration of this medicine.

The medicine contains 2.5 mg sodium (the major ingredient of cooking salt/table salt) per each ml of the concentrated solution.

The medicine contains 10 mg sodium in each 4 ml vial. This guantity is equivalent to 0.5% of the recommended maximal daily dietary intake of sodium for an adult. The medicine contains 25 mg sodium in each 10 ml vial. This quantity is equivalent to 1.5% of the recommended maximal daily dietary intake of sodium

3. HOW SHOULD YOU USE THE MEDICINE?

Always use the medicine according to the doctor's instructions

Check with your doctor or pharmacist if you are not sure about the dose or about how to take this medicine. The dosage and treatment regimen will be determined only by the doctor.

- OPDIVO is administered by healthcare professionals directly into the vein through an intravenous (IV) line over 60 minutes or 30 minutes, depending on the dosage and frequency determined by the doctor.
- When OPDIVO is used alone, it is usually given every 2 weeks or every 4 weeks depending on the dose you are receiving. • When OPDIVO is used in combination with ipilimumab, except for treating
- netastatic non-small cell lung cancer and for treating some cases of malignant pleural mesothelioma (see below), OPDIVO is usually given every 3 weeks for a total of 4 treatment doses. Ipilimumab will be given on the same day. After that, OPDIVO will be given alone every 2 weeks or every 4 weeks depending on the dose you are receiving. For treatment of non-small cell lung cancer before surgery (neoadjuvant),
- OPDIVO is used in combination with chemotherapy every 3 weeks for 3 treatment cvcles.
- For treatment of metastatic non-small cell lung cancer that has spread to other parts of your body, when OPDIVO is used in combination with ipilimumab, OPDIVO is given every 3 weeks, and ipilimumab is given every 6 weeks for up to 2 years. You will also need to receive chemotherapy every 3 weeks for
- 2 treatment cvcles. • For treatment of malignant pleural mesothelioma, OPDIVO is given every 2 weeks or every 3 weeks and ipilimumab is given every 6 weeks for up to 2
- For treatment of advanced renal cell carcinoma, when OPDIVO is used in combination with cabozantinib, OPDIVO is usually given every 2 weeks or every 4 weeks depending on the dose you are receiving. Cabozantinib is given once daily by mouth.
- When OPDIVO is used in combination with fluoropyrimidine and platinum-based chemotherapy for treating esophageal squamous cell carcinoma, OPDIVO is given every 2 weeks or every 4 weeks for up to 2 years.
- When OPDIVO is used in combination with ipilimumab for treating esophageal squamous cell carcinoma, OPDIVO is given every 2 weeks or every 3 weeks and ipilimumab is given every 6 weeks for up to 2 years.
- For treatment of gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma, when OPDIVO is given in combination with fluoropyrimidine and platinum containing chemotherapy, OPDIVO is given every 2 weeks or every 3 weeks depending on the dose you are receiving for
- up to 2 years. Chemotherapy will be given on the same day. • The treating doctor will decide how many treatments you need.
- If you are unable to come in for your scheduled treatment, or if you forget to come in for treatment, contact the treating doctor as soon as possible to schedule a new appointment for treatment.

Do not exceed the recommended dose

Adhere to the treatment regimen as recommended by the doctor.

If you have taken an overdose, or if a child has accidentally swallowed some medicine, refer immediately to a doctor or proceed to a hospital emergency room and bring the package of the medicine with you. Do not take medicines in the dark! Check the label and dose every time you take a medicine. Wear glasses if you need them.

If you have further questions regarding use of the medicine, consult the doctor or pharmacist.

As with any medicine, use of OPDIVO may cause side effects in some users. Do not be alarmed by the list of side effects. You may not suffer from any of them. OPDIVO may cause serious side effects, including:

Severe side effects related to immune system activity

OPDIVO is a medicine that treats certain types of cancer by activating your immune system. OPDIVO may cause your immune system to attack healthy tissues and organs in any area of your body and can affect the way they work. These problems may sometimes become serious or lead to death. These problems may appear at any time during treatment or even after treatment has ended. You may experience more than one of these problems at the same time. Some of these problems may happen more often when OPDIVO is used in combination with additional treatment.

Immediately contact the treating doctor if you experience any new signs or symptoms or worsening signs or symptoms, including:

- Lung problems
- onset of cough or worsening cough shortness of breath
- chest pain

Liver problems.

severe nausea or vomitin

dark urine (tea colored)

eye sensitivity to light

increased sweating

weight gain or weight loss

feeling more thirsty or hungry than usual

extreme tiredness

eve problems

rapid heartbeat

Hormone glands problems

Intestinal problems. diarrhea (loose stools) or more frequent bowel movements than usual stools that are black, tarry, sticky, or have blood or mucus • severe stomach-area (abdominal) pain or tenderness

· yellowing of your skin or the whites of your eyes

bleeding or bruising more easily than normal

• pain on the right side of the stomach area (abdomen)

• headaches that will not go away or unusual headaches

• constipation	• adrenal glands insufficiency (decrease in the level of hormones secreted by	• liver problems. See "Liver problems" in section "Severe side effects related to	מידע לצוות הרפואי
 voice changes and gets deeper and lower dizziness or fainting changes in paced as babavias such as deepended any drive initability as 	adrenal glands located above the kidneys) sudden death section intertional blocking 	immune system activity" • liver toxicity • recharge pairs availing or bligtering of the bands or fact	معلومات للطاقم الطبي Information for Healthcare Professionals
 changes in mood or behavior, such as decreased sex drive, irritability or forgetfulness 	gastrointestinal bleeding septic shock	 rash, redness, pain, swelling or blistering of the hands or feet sores or ulcers in the mouth (stomatitis) 	Preparation and Administration • under refrigeration at 2°C to 8°C (36°F to 46°F) and protected from light for
Kidney problems. decrease in your amount of urine 	 esophageal fistula Side effects occurring when OPDIVO is administered in combination with 	rash itching	Visually inspect for particulate matter and discoloration. OPDIVO is a clear to opalescent, colorless to pale-yellow solution. Discard if cloudy, discolored, or
 blood in your urine swelling of your ankles 	ipilimumab include: Very common side effects, affect more than 1 in 10 users	 high blood pressure low thyroid hormone levels [hypothyroidism (decreased activity of the thyroid 	contains extraneous particulate matter other than a few translucent-to-white, • Do not freeze.
loss of appetite	feeling tired	gland)] that can cause fatigue and weight gain • pain in muscles, bones and joins	Preparation • Administration • Administration
Skin problems. • rash	• fever • swelling (edema)	 decreased appetite change in the sense of taste 	Withdraw the required volume of OPDIVO and transfer into an intravenous container. Ditte opply(o) with a these 0.0% Optime Oblacide Interview 1900 as 5%
 itching skin blistering or skin peeling 	 rash itching, widespread itching 	headache cough	 Dilute OPDIVO with either 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP to prepare an infusion with a final concentration Administer OPDIVO in combination with other therapeutic agents as follows: Administer OPDIVO in combination with other therapeutic agents as follows:
 painful sores or ulcers in mouth or nose, throat, or genital area Problems may also happen in other organs and tissues. These are not 	• dry skin • diarrhea	 voice disorders (difficulty speaking due to disorders of the pharynx, vocal cords, tongue or mouth) 	ranging from 1 mg/mL to 10 mg/mL. The total volume of infusion must not exceed 160 mL.
all of the signs and symptoms of immune system problems that may	 nausea vomiting 	upper respiratory tract infection	 For adult and pediatric patients with body weight 40 kg or greater, do not exceed a total volume of infusion of 160 mL. With platinum-doublet chemotherapy: administer OPDIVO first followed by platinum doublet chemotherapy on the same day.
happen with OPDIVO. Contact the treating doctor right away for any new or worsening signs or symptoms, which may include:	 stomach-area (abdominal) pain constipation 	 abnormal laboratory test results Common side effects, affect 1-10 in 100 users: 	• For adult and pediatric patients with body weight less than 40 kg, do not exceed a total volume of infusion of 4 mL/kg of body weight. • With ipilimumab and platinum-doublet chemotherapy: administer OPDIVO first followed by ipilimumab and then platinum-doublet chemotherapy on
 chest pain, irregular heartbeat, shortness of breath or swelling of ankles confusion, sleepiness, memory problems, changes in mood or behavior, stiff 	 swollen stomach (abdomen) due to fluid accumulation (ascites) dry mouth 	 pneumonia pulmonary embolism (blood clot in the lungs) 	 Mix diluted solution by gentle inversion. Do not shake. Discard partially used vials or empty vials of OPDIVO. With fluoropyrimidine- and platinum-containing chemotherapy: administer
 neck, balance problems, tingling or numbness of the arms or legs double vision, blurry vision, sensitivity to light, eye pain, changes in eyesight 	 dyspepsia difficulty swallowing 	 inflammation of the lung tissues (pneumonitis) characterized by coughing and difficulty breathing, shortness of breath and cough 	The product does not contain a preservative. OPDIVO first followed by fluoropyrimidine- and platinum-containing chemotherapy on the same day.
 severe or persistent muscle pain or weakness, muscle cramps low red blood cells count, predisposition to bruising 	 ulcers or sores in the mouth (stomatitis) inflammation of the colon (colitis) 	urinary tract infection	 at room temperature and room light for no more than 8 hours from the time of preparation to end of the infusion. Discard diluted solution if not used Use separate infusion bags and filters for each infusion. Flush the intravenous line at end of infusion.
Getting medical treatment right away may help prevent these problems from becoming more serious.	pain in muscles, bones, and joints cough, cough with phleam	Uncommon side effects, affect 1-10 in 1000 users: • death due to side effects	• Do not co-administer other drugs through the same intravenous line.
The treating doctor will check you for these problems during treatment with OPDIVO. The doctor may treat you with corticosteroids or hormone replacement	 shortness of breath, shortness of breath upon exertion 	Side effects occurring when OPDIVO is administered in combination with chemotherapy containing fluoropyrimidine and platinum include:	
medicines. If the side effects are severe, the doctor may delay or completely	 pneumonia upper respiratory tract infection 	Very common side effects, affect more than 1 in 10 users: • numbness, pain, tingling or burning in the hands or feet (peripheral neuropathy)	
stop treatment with OPDIVO. Severe infusion-related side effects	 inflammation of the lung tissues (pneumonitis) characterized by coughing and difficulty breathing, shortness of breath and cough 	headache	
Tell your treating doctor or nurse immediately if you experience any of the symptoms listed below when receiving the OPDIVO infusion:	decreased appetiteheadache	 nausea diarrhea 	
 chills or shaking itching or rash 	• dizziness • flu	vomiting difficulty swallowing	
flushing flushing shortness of breath or wheezing	 flu-like illness weakness, generally feeling unwell 	stomach-area (abdominal pain)constipation	
• dizziness	chills low blood pressure	 ulcers or sores in the mouth (stomatitis) feeling tired 	
• feel like passing out • fever • heek of pools	 low block pressure low thyroid hormone levels [hypothyroidism (decreased activity of the thyroid gland)] that can cause fatigue and weight gain 	feverswelling (edema)	
 back or neck pain Complications of stem cell transplantation using donor stem cells 	 high thyroid hormone levels [hyperthyroidism (increased activity of the thyroid dand)] that can cause rapid heart rate, sweating and weigh loss 	 decreased appetite decreased weight 	
(allogeneic). These complications may be severe and may lead to death. These complications	• adrenal glands insufficiency (decrease in the level of hormones secreted by	pain in muscles, bones and joints rash	
may happen if the transplantation was performed either before or after treatment with OPDIVO. Your treating doctor will monitor you for signs of complications if	adrenal glands located above the kidneys) • decreased weight	itching • hair loss	
you have undergone an allogeneic stem cell transplant.	difficulty sleepingabnormal laboratory test results	 rash, redness, pain, swelling or blistering of the hands or feet 	
Additional side effects: Side effects of OPDIVO when used alone include:	Common side effects, affect 1-10 in 100 users: vitiligo, a disease in which light patches appear on the skin 	cough, cough with phlegm upper respiratory tract infection	
Very common side effects, affect more than 1 in 10 users: • feeling tired	 high blood pressure high level of sugar in blood (hyperglycemia) 	pneumonia difficulty sleeping	
weakness, generally feeling unwell fever	 intestinal perforation accumulation of fluid in the pleural cavity around the lungs (pleural effusion) 	 abnormal laboratory test results Common side effects, affect 1-10 in of 100 users: 	
 swelling (edema), including swelling of the hands, ankles or feet (peripheral edema) 	which may cause shortness of breath and sometimes also chest pain and	 fever due to low level of neutrophils, a type of white blood cells (febrile neutropenia) 	
• diarrhea • nausea	fever • pulmonary embolism (blood clot in the lungs)	 inflammation of the lung tissues (pneumonitis) characterized by coughing and difficulty breathing, shortness of breath and cough 	
• vomiting	 inflammation of the pituitary gland (hypophysitis) swollen stomach 	 low thyroid hormone levels [hypothyroidism (decreased activity of the thyroid gland)] that can cause fatigue and weight gain 	
 stomach-area (abdominal) pain constipation 	 dehydration acute kidney injury 	esophageal stricture	
• swollen stomach • dyspepsia	hepatic eventabnormal liver function	 acute kidney injury death due to side effects 	
 difficulty swallowing rash 	 bleeding from esophageal varices death due to side effects 	For combined treatment with OPDIVO and ipilimumab, see also patient leaflet of ipilimumab.	
 itchy skin, including widespread itching vitiligo, a disease in which light patches appear on the skin 	 muscle pain, muscle weakness not caused by exercise (myopathy) muscles inflammation (myositis) 	For combined treatment with OPDIVO and cabozantinib, see also patient leaflet of cabozantinib.	
 erythema manifested by skin redness and inflammation pain in muscles, bones, and joints 	 nerve inflammation (neuritis) paralysis of the fibular nerve in the leg characterized by pain in the calf, 	These are not all the possible side effects of OPDIVO. For medical information	
headache dizziness	decreased sensation or numbness, muscle weakness, and in severe cases foot drop or typical limping (peroneal nerve palsy)	on side effects, contact your treating doctor. If you experience any side effect, if any side effect gets worse, or if you	
upper respiratory tract infection nasal congestion	 Sjogren's syndrome, a disease in which the immune system attacks mainly lacrimal and salivary glands 	suffer from a side effect not mentioned in the leaflet, consult with the doctor.	
 pneumonia, including pneumonia involving the bronchi cough, cough with phlegm 	 chronic joints inflammation usually involving the spinal joints (spondyloarthropathy) 	Side effects can be reported to the Ministry of Health by clicking on the "Reporting side effects following drug treatment" link found on the Ministry of Health homepage	
 shortness of breath, shortness of breath upon exertion decreased appetite 	 numbness, pain, tingling or burning in the hands or feet (peripheral 	(www.health.gov.il) that directs you to the online form for reporting side effects,	
decreased weight back pain	neuropathy) infusion-related reactions 	or through the following link: https://sideeffects.health.gov.il 5. HOW SHOULD THE MEDICINE BE STORED?	
 back pain low thyroid hormone levels [hypothyroidism (decreased activity of the thyroid gland)] that can cause fatigue and weight gain 	Uncommon side effects, affect 1-10 in 1000 users: • inflammation of the brain (encephalitis)	 Avoid poisoning! This medicine, and all other medicines, must be stored in a safe place out of the reach and sight of children and/or infants, in order to 	
• high thyroid hormone levels [hyperthyroidism (increased activity of the thyroid	 muscle inflammation leading to necrosis eye pain and redness - inflammation of the uvea (uveitis) 	avoid poisoning. Do not induce vomiting unless explicitly instructed to do so by a doctor!	
 gland)] that can cause rapid heart rate, sweating and weight loss thyroid gland problems, including thyroid gland inflammation (thyroiditis) 	Side effects occurring when OPDIVO is administered in combination with chemotherapy include:	 Do not use the medicine after the expiry date (exp. date) that appears on the package. The expiry date refers to the last day of that month. 	
abnormal renal function urinary tract infection liver information (honoritin)	Very common side effects, affect more than 1 in 10 users:	Storage conditions: Refrigerate at 2°C-8°C. Protect from light by storing the	
 liver inflammation (hepatitis) high blood pressure bigh blood pressure 	feeling tired generally feeling unwell	vial in the original package until time of use.Do not freeze or shake.Once the infusion has been prepared: complete administration of the infusion	
 high level of sugar in blood (hyperglycemia) difficulty sleeping 	nausea constipation	 Once the infusion has been prepared: complete administration of the infusion within 7 days of preparation. In the event that the infusion is not administered immediately. ORD/VC can be started ofter preparation; 	
 numbness, pain, tingling or burning in the hands or feet (peripheral neuropathy) abnormal laboratory test results 	 vomiting decreased appetite 	immediately, OPDIVO can be stored after preparation: • at room temperature (20°C-25°C) and room light for a period of no more those 0 beaution (sub of the 2 deau) for the store of the second of th	
infusion-related reactions Common side effects, affect 1-10 in 100 users:	• rash • hair loss	than 8 hours (out of the 7 days) from the time of preparation until the end of infusion administration.	
 irregular heartbeat inflammation of the eye iris and ciliary body (iridocyclitis) 	 numbness, pain, tingling or burning in the hands or feet (peripheral neuropathy) abnormal laboratory test results 	or • refrigerated at a temperature of 2°C-8°C and protected from light for a period	
 inflammation of the order is and only body (modely body) inflammation of the nerves manifested by numbress, weakness, tingling, or pain accompanied by burning sensation (sensory and peripheral neuropathy) 	Common side effects, affect 1-10 in 100 users: • pneumonia	of up to 7 days from the time of preparation until the end of administration. • Do not dispose of medicines via wastewater or waste bin. Ask the pharmacist	
 intestinal perforation ulcers or sores in the mouth (stomatitis) 	 severe allergic reaction (anaphylactic reaction) acute kidney injury 	how to dispose of medicines no longer in use. These measures will help to protect the environment.	
 encers of soles in the mount (storiatus) severe skin condition that causes red, sometimes itchy spots, similar to the rash of measles, which starts on the limbs and sometimes on the face and the 	Side effects occurring when OPDIVO is administered in combination with	6. FURTHER INFORMATION:	
rest of the body (erythema multiforme)	ipilimumab and chemotherapy include: Very common side effects, affect more than 1 in 10 users:	In addition to the active ingredient, the medicine also contains: Mannitol, sodium citrate dihydrate, sodium chloride, polysorbate 80, pentetic acid	
 severe inflammation of the skin manifested by redness and peeling of extensive skin areas (exfoliative dermatitis) 	feeling tired fever	and water for injection. May contain hydrochloric acid and/or sodium hydroxide. What the medicine looks like and the contents of the package:	
 psoriasis accumulation of fluid in the pleural cavity around the lungs (pleural effusion) which many subscriptions of hearth and cavetimes also proved that are and 	 pain in muscles, bones, and joints nausea 	A clear to opalescent, colorless to slightly yellowish liquid. The liquid may contain a few particles.	
which may cause shortness of breath and sometimes also chest pain and fever	diarrhea constipation	OPDIVO is available in a 10 ml (100 mg) single-use vial and a 4 ml (40 mg) single-use vial.	
 pulmonary embolism (blood clot in the lungs) inflammation of the lung tissues (pneumonitis) characterized by coughing and 	• consupation • vomiting • stomach-area (abdominal) pain	Manufacturer's name and address: Bristol-Myers Squibb Holdings Pharma Ltd.,	
difficulty breathing, shortness of breath and coughinterstitial lung disease characterized by shortness of breath and dry cough,	• rash	Liability Company, Manati, Puerto Rico, USA. Registration holder's name and address: Bristol-Myers Squibb (Israel) Ltd.,	
and causing lung scarring • respiratory failure (extreme difficulty breathing)	itching, including widespread itching hair loss descread exection	18 Aharon Bart St. P.O. Box. 3361, Kiryat Arye, Petach Tikva 4951448.	
acute renal injury sepsis	decreased appetite cough	Registration number of the medicine in the National Drug Registry of the Ministry of Health:	
 general health condition deterioration intestinal obstruction (small intestine obstruction) 	 shortness of breath low thyroid hormone levels [hypothyroidism (decreased activity of the thyroid 	153-55-34333-00 Revised in December 2023 according to MOH guidelines.	
inflammation of the colon (colitis) ilver problems	gland)] that can cause fatigue and weight gain • headache	· · · · · · · · · · · · · · · · · · ·	
• dry skin	dizziness abnormal laboratory test results		

Common side effects, affect 1-10 in 100 users:

abnormal laboratory test results

pneumonia

neutropenia)

acute kidney injury

death due to side effects

stomach-area (abdominal) pain

cabozantinib include

nausea

vomiting

dyspepsia

feeling tired or weat

• fever due to low level of neutrophils, a type of white blood cell (febrile

• inflammation of the lung tissues (pneumonitis) characterized by coughing and

difficulty breathing, shortness of breath and cough respiratory failure (extreme difficulty breathing)

Side effects occurring when OPDIVO is administered in combination with

Very common side effects, affect more than 1 in 10 users: